CoTherix, a sister company of Actelion Pharmaceuticals US, Inc. and part of the Janssen Pharmaceutical Company of Johnson & Johnson, specializes in the distribution of authorized generic versions of pharmaceutical products. Located in South San Francisco, a hub for pharmaceutical and biotechnology development, CoTherix operates within the highly regulated pharmaceutical industry. The company ensures that its products meet stringent safety and regulatory standards, as evidenced by its involvement in the Bosentan REMS program, which includes all brand and generic bosentan products. This program is mandated by the FDA to manage the risks associated with hepatotoxicity and embryo-fetal toxicity. CoTherix's business model revolves around the distribution of these authorized generics, serving healthcare providers and patients who require these medications. The company generates revenue through the sale of these generic pharmaceuticals, leveraging its regulatory compliance and safety-focused approach to maintain market trust and reliability.

Keywords: authorized generics, pharmaceutical distribution, regulatory compliance, safety-focused, Bosentan REMS, FDA, hepatotoxicity, embryo-fetal toxicity, healthcare providers, South San Francisco.